Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare lung disease: protein infusions may slow emphysema

NCT ID NCT01983241

Ongoing Disease control Sponsor: Grifols Therapeutics LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether weekly infusions of Alpha-1 MP (a protein replacement) can slow lung damage in 345 people with emphysema caused by Alpha-1 antitrypsin deficiency. Participants receive one of two doses or a placebo for three years, with lung CT scans tracking changes. The goal is to see if the treatment preserves lung function and reduces flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Alpha-1 MP (Prolastin-C)

What this could lead to

If it works, this could provide a new treatment option to slow lung damage in people with Alpha-1 antitrypsin deficiency-related emphysema.

What could go wrong

This is a late-stage trial, but the treatment is not a cure—patients will need ongoing therapy. Results may not show significant benefit over placebo, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY EMPHYSEMA IN ALPHA-1 PI DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alpha 1-antitrypsin deficiency pulmonary emphysema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY EMPHYSEMA IN ALPHA-1 PI DEFICIENCY

Contacts and locations

Locations

  • Grifols Investigative Site

    Phoenix, Arizona, 85013, United States

  • Grifols Investigative Site

    Gainesville, Florida, 32610, United States

  • Grifols Investigative Site

    Leesburg, Florida, 34748, United States

  • Grifols Investigative Site

    Miami, Florida, 33136, United States

  • Grifols Investigative Site

    St Louis, Missouri, 63110, United States

  • Grifols Investigative Site

    Wilmington, North Carolina, 28401, United States

  • Grifols Investigative Site

    Portland, Oregon, 97239, United States

  • Grifols Investigative Site

    Hershey, Pennsylvania, 17033, United States

  • Grifols Investigative Site

    Charleston, South Carolina, 29425, United States

  • Grifols Investigative Site

    Tyler, Texas, 75708, United States

  • Grifols Investigative Site

    Vicente López, Buenos Aires, B1602DOH, Argentina

  • Grifols Investigative Site

    Córdoba, Córdoba Province, 5000, Argentina

  • Grifols Investigative Site

    Sydney, New South Wales, 2010, Australia

  • Grifols Investigative Site

    Chermside, Queensland, 4032, Australia

  • Grifols Investigative Site

    Adelaide, South Australia, 5000, Australia

  • Grifols Investigative Site

    Fitzroy, Victoria, 3065, Australia

  • Grifols Investigative Site

    Nedlands, Western Australia, 6009, Australia

  • Grifols Investigative Site

    Santo André, São Paulo, 09060-650, Brazil

  • Grifols Investigative Site

    São Paulo, São Paulo, 04023-061, Brazil

  • Grifols Investigative Site

    São Paulo, São Paulo, 05403-000, Brazil

  • Grifols Investigative Site

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • Grifols Investigative Site

    Halifax, Nova Scotia, B3H3A8, Canada

  • Grifols Investigative Site

    Toronto, Ontario, M5T3A11, Canada

  • Grifols Investigative Site

    Arhus C, 8000, Denmark

  • Grifols Investigative Site

    Hellerup, 2900, Denmark

  • Grifols Investigative Site

    Tallinn, 13419, Estonia

  • Grifols Investigative Site

    Tartu, 51014, Estonia

  • Grifols Investigative Site

    Turku, 20520, Finland

  • Grifols Investigative Site

    Pessac, Gironde, 33604, France

  • Grifols Investigative Site

    Bron, Rhone, 69500, France

  • Grifols Investigative Site

    Heidelberg, Baden-Wurttemberg, 69126, Germany

  • Grifols Investigative Site

    Marburg, Hesse, 35043, Germany

  • Grifols Investigative Site

    Essen, North Rhine-Westphalia, 45239, Germany

  • Grifols Investigative Site

    Homburg Saar, 66421, Germany

  • Grifols Investigative Site

    Chisinau, 2025, Moldova

  • Grifols Investigative Site

    Auckland, 1051, New Zealand

  • Grifols Investigative Site

    Christchurch, 8013, New Zealand

  • Grifols Investigative Site

    Hamilton, 3240, New Zealand

  • Grifols Investigative Site

    Krakow, 31-066, Poland

  • Grifols Investigative Site

    Warsaw, 01-138, Poland

  • Grifols Investigative Site

    Oradea, 410176, Romania

  • Grifols Investigative Site

    Timișoara, 300312, Romania

  • Grifols Investigative Site

    Barnaul, 656038, Russia

  • Grifols Investigative Site

    Moscow, 105077, Russia

  • Grifols Investigative Site

    Yaroslavl, 150003, Russia

  • Grifols Investigative Site

    Oviedo, Principality of Asturias, 33011, Spain

  • Grifols Investigative Site

    Barakaldo, Vizcaya, 48903, Spain

  • Grifols Investigative Site

    Gothenburg, 41345, Sweden

  • Grifols Investigative Site

    Linköping, 587 58, Sweden

  • Grifols Investigative Site

    Malmö, 20502, Sweden

  • Grifols Investigative Site

    Stockholm, 11361, Sweden

  • Grifols Investigative Site

    Uppsala, 752 37, Sweden